KR960022559A - 슈도모나스 에루지노사 막 단백질로부터 유도된 면역원성 하이브리드 단백질 OprF-Oprl - Google Patents
슈도모나스 에루지노사 막 단백질로부터 유도된 면역원성 하이브리드 단백질 OprF-Oprl Download PDFInfo
- Publication number
- KR960022559A KR960022559A KR1019950049536A KR19950049536A KR960022559A KR 960022559 A KR960022559 A KR 960022559A KR 1019950049536 A KR1019950049536 A KR 1019950049536A KR 19950049536 A KR19950049536 A KR 19950049536A KR 960022559 A KR960022559 A KR 960022559A
- Authority
- KR
- South Korea
- Prior art keywords
- pseudomonas aeruginosa
- protein
- hybrid protein
- carboxy terminal
- membrane protein
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract 13
- 102000004169 proteins and genes Human genes 0.000 title claims abstract 13
- 241000589517 Pseudomonas aeruginosa Species 0.000 title claims abstract 4
- 108010052285 Membrane Proteins Proteins 0.000 title 1
- 230000002163 immunogen Effects 0.000 title 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract 8
- 101710203389 Outer membrane porin F Proteins 0.000 claims abstract 4
- 101710160104 Outer membrane protein F Proteins 0.000 claims abstract 4
- 108010058634 Bacteria outer membrane lipoprotein I Proteins 0.000 claims abstract 3
- 150000001413 amino acids Chemical class 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 208000032536 Pseudomonas Infections Diseases 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/104—Pseudomonadales, e.g. Pseudomonas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/823—Bacterial vaccine for bovine species, e.g. cattle
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/824—Bacterial vaccine for ovine species, e.g. sheep
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/825—Bacterial vaccine for porcine species, e.g. swine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/826—Bacterial vaccine for avian species, e.g. poultry or other birds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/828—Bacterial vaccine for canidae or mustelidae, e.g. dogs, foxes, minks
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/829—Bacterial vaccine for equine species, e.g. horses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Abstract
본 발명은 슈도모나스 에루지노사 외막 단백질 F(OprF)의 카복시-말단 부분의 카복시 말단 끝에 그의 아미노 말단이 융합된 슈도모나스 에루지노사 외막 단백질 I(OprI)를 포함하는 하이브리드 단백질 및 상기 하이브리드 단백질에 대한 모노클로날 또는 폴리클로날 항체에 관한 것이다. 단백질 및 하이브리드 단백질 및 하이브리드 단백질에 대한 항체 모두는 실험 동물 또는 사람을 슈도모나스 에루지노사 감염으로부터 보호한다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 피. 에루지노사(P. aeruginosa) 외막 단백질의 제작된 재조합 융합 단백질의 개략도이다.
Claims (8)
- 슈도모나스 에루지노사(Pseudomonas aeruginosa)외막 단백질 F의 카복시 말단 부분의 카복시 말단 끝에 그의 아미노 말단이 융합된 슈도모나스 에루지노사 외막 단백질 I을 포함하는데, 이때 상기 카복시 말단 부분이 190번 350번 아미노산 서열을 포함하는 하이브리드 단백질.
- 제1항에 있어서, 상기 카복시 말단 부분이 190번 내지 342번 아미노산 서열인 하이브리드 단백질.
- 슈도모나스 에루지노사 외막 단백질 F의 카복시 말단 부분의 카복시 말단 끝에 그의 아미노 말단이 융합된 슈도모나스 에루지노사 외막 단백질 I을 포함하는데, 이때 상기 카복시 말단 부분이 SEEI(212번 내지 240번 아미노산), SEE2(243번 내지 256번 아미노산), SEE3(285번 내지 298번 아미노산) 및 SEE4(332번 내지 350번 아미노산)로 이루어지는 그룹으로 부터 선택되는 하나 이상의 표면-노출된 B-세포 에피토프를 포함하는 하이브리드 단백질.
- 제1항 내지 제3항 중의 어느 한 항에 따른 하리브리드 단백질을 포함하는 백신.
- 제1항 내지 제3항 중의 어느 한 항에 따른 하이브리드 단백질에 대한 모노클로날 또는 폴리클로날 항체.
- 제5항에 따른 항체를 포함하는 백신.
- 제1항 내지 제3항 중 어느 한 항에 따른 하이브리드 단백질을 암호화하는 핵산.
- 진핵 세포 또는 원핵 세포에서 제7항에 따른 핵산을 발현시키는 것을 포함하는, 제1항 내지 제3항 중의 어느 한 항에 따른 하이브리드 단백질의 제조방법.※ 참고사항:최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94120023 | 1994-12-16 | ||
EP94120023.0 | 1994-12-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR960022559A true KR960022559A (ko) | 1996-07-18 |
Family
ID=8216542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019950049536A KR960022559A (ko) | 1994-12-16 | 1995-12-14 | 슈도모나스 에루지노사 막 단백질로부터 유도된 면역원성 하이브리드 단백질 OprF-Oprl |
Country Status (8)
Country | Link |
---|---|
US (2) | US5955090A (ko) |
EP (1) | EP0717106B1 (ko) |
JP (2) | JP3712244B2 (ko) |
KR (1) | KR960022559A (ko) |
AT (1) | ATE190657T1 (ko) |
AU (1) | AU4041995A (ko) |
CA (1) | CA2165401C (ko) |
DE (1) | DE69515613T2 (ko) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE207538T1 (de) * | 1995-02-09 | 2001-11-15 | Behringwerke Ag | Verfahren zur produktion von proteinen |
GB9701489D0 (en) | 1997-01-24 | 1997-03-12 | Auspharm Int Ltd | Antigen |
KR100461710B1 (ko) * | 1997-09-13 | 2005-09-28 | 씨제이 주식회사 | 신규한 녹농균 세포 외막 단백질 유전자 및 이를 이용한 녹농균 감염 예방용 백신 및 녹농균 감염증 치료제 |
GB9915044D0 (en) * | 1999-06-25 | 1999-08-25 | Smithkline Beecham Biolog | Novel compounds |
EP1078988A1 (en) * | 1999-08-27 | 2001-02-28 | Academia Sinica | Pseudomonas fusion protein vaccines |
AU2001248314B2 (en) * | 2000-02-18 | 2004-08-19 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Use of Oprl lipoprotein from pseudomonas as a Th1 inducing natural adjuvant for heterologous antigens |
EP1343894A4 (en) * | 2000-11-02 | 2005-05-04 | Univ Singapore | AOPB GENE, PROTEIN, HOMOLOGISTS, FRAGMENTS AND VARIANTS THEREOF, AND THE USE THEREOF FOR PRESENTATION ON THE CELL SURFACE |
JP2002316944A (ja) * | 2001-04-17 | 2002-10-31 | Chemo Sero Therapeut Res Inst | ヒトポリクローナル抗体組成物 |
EP1790659B1 (en) | 2001-11-13 | 2013-07-31 | ID Biomedical Corporation | Polypeptides of pseudomonas aeruginosa |
CA2784450C (en) * | 2001-11-13 | 2016-09-13 | Id Biomedical Corporation | Polypeptides of pseudomonas aeruginosa |
US7405039B2 (en) | 2002-02-07 | 2008-07-29 | Austin Health | Viral variants with altered susceptibility to nucleoside analogs and uses thereof |
EP2033967A1 (en) | 2002-04-12 | 2009-03-11 | Melbourne Health | Hepatitis B viral variants with reduced susceptibility to nucleoside analogs and uses thereof |
WO2006105597A1 (en) | 2005-04-08 | 2006-10-12 | Melbourne Health | Variants of hepatitis b virus with resistance to anti-viral nucleoside agents and applications thereof |
US8211443B2 (en) | 2005-04-08 | 2012-07-03 | Melbourne Health | Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof |
KR20080068048A (ko) | 2005-10-28 | 2008-07-22 | 메이지 세이카 가부시키가이샤 | 녹농균의 외막 단백질 pa5158 |
WO2007070372A2 (en) * | 2005-12-09 | 2007-06-21 | Entremed, Inc. | Compositions and methods for inhibiting cellular proliferation |
SG170804A1 (en) | 2006-03-30 | 2011-05-30 | Meiji Seika Kaisha | Pseudomonas aeruginosa outer membrane protein pa0427 |
KR20100028558A (ko) * | 2007-06-29 | 2010-03-12 | 메이지 세이카 가부시키가이샤 | 녹농균 외막 단백질 pa4710 |
KR20100100941A (ko) | 2007-12-25 | 2010-09-15 | 메이지 세이카 가부시키가이샤 | 녹농균의 ⅲ형 분비 장치 구성 단백질 pa1698 |
US9096659B2 (en) | 2009-03-18 | 2015-08-04 | Wake Forest University Health Sciences | Flagellin fusion proteins and use thereof to induce immune responses against Pseudomonas aeruginosa |
JP5893640B2 (ja) * | 2010-12-23 | 2016-03-23 | ファルネファ オーストリア ゲーエムベーハー | Oprf/i試薬と入院および他の患者におけるその利用 |
EP2686339A1 (en) * | 2011-03-18 | 2014-01-22 | Valneva Austria GmbH | Novel oprf/i fusion proteins, their preparation and use |
RU2529359C2 (ru) * | 2012-09-19 | 2014-09-27 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" Российской академии медицинских наук (ФГБУ "НИИВС им. И.И. Мечникова" РАМН) | РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pPA-OPRF-ETA, КОДИРУЮЩАЯ СИНТЕЗ РЕКОМБИНАНТНОГО БЕЛКА OPRF-ETA Pseudomonas aeruginosa, ШТАММ Escherichia coli PA-OPRF-ETA - ПРОДУЦЕНТ РЕКОМБИНАНТНОГО БЕЛКА OPRF-ETA Pseudomonas aeruginosa И СПОСОБ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО БЕЛКА OPRF-ETA Pseudomonas aeruginosa |
PL2925355T3 (pl) | 2012-11-30 | 2018-06-29 | Glaxosmithkline Biologicals S.A. | Antygeny pseudomonas i połączenia antygenów |
CA2959165A1 (en) * | 2014-08-29 | 2016-03-03 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind oprf and opri |
WO2016193402A1 (en) * | 2015-06-03 | 2016-12-08 | Valneva Austria Gmbh | Pseudomonas vaccine |
WO2017005670A1 (en) * | 2015-07-04 | 2017-01-12 | Evaxion Biotech Aps | Proteins and nucleic acids useful in vaccines targeting pseudomonas aeruginosa |
GB201518668D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3718591A1 (de) * | 1987-06-03 | 1988-12-15 | Behringwerke Ag | Aeusseres membranprotein f von pseudomonas aeruginosa |
DE3829616C2 (de) * | 1988-09-01 | 1996-08-29 | Behringwerke Ag | Lipoprotein I (OMPI) von Pseudomonas aeruginosa |
US5196320A (en) * | 1989-09-20 | 1993-03-23 | Abbott Biotech, Inc. | Method of producing engineered binding proteins |
WO1993024636A1 (en) * | 1992-05-29 | 1993-12-09 | The University Of British Columbia | Use of protein oprf for bacterial cell surface expression of oligopeptides |
-
1995
- 1995-11-17 DE DE69515613T patent/DE69515613T2/de not_active Expired - Lifetime
- 1995-11-17 EP EP95118098A patent/EP0717106B1/en not_active Expired - Lifetime
- 1995-11-17 AT AT95118098T patent/ATE190657T1/de active
- 1995-12-14 AU AU40419/95A patent/AU4041995A/en not_active Abandoned
- 1995-12-14 US US08/572,447 patent/US5955090A/en not_active Expired - Lifetime
- 1995-12-14 KR KR1019950049536A patent/KR960022559A/ko not_active Application Discontinuation
- 1995-12-15 CA CA2165401A patent/CA2165401C/en not_active Expired - Lifetime
- 1995-12-18 JP JP32915495A patent/JP3712244B2/ja not_active Expired - Fee Related
-
1999
- 1999-03-10 US US09/267,747 patent/US6300102B1/en not_active Expired - Lifetime
-
2004
- 2004-12-15 JP JP2004363728A patent/JP3762779B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP3762779B2 (ja) | 2006-04-05 |
US5955090A (en) | 1999-09-21 |
JP2005097321A (ja) | 2005-04-14 |
EP0717106A1 (en) | 1996-06-19 |
CA2165401A1 (en) | 1996-06-17 |
US6300102B1 (en) | 2001-10-09 |
ATE190657T1 (de) | 2000-04-15 |
DE69515613T2 (de) | 2000-11-30 |
EP0717106B1 (en) | 2000-03-15 |
JPH08245699A (ja) | 1996-09-24 |
AU4041995A (en) | 1996-06-27 |
CA2165401C (en) | 2010-05-11 |
DE69515613D1 (de) | 2000-04-20 |
JP3712244B2 (ja) | 2005-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR960022559A (ko) | 슈도모나스 에루지노사 막 단백질로부터 유도된 면역원성 하이브리드 단백질 OprF-Oprl | |
WO1995029193A3 (en) | Melanoma antigens | |
KR910016343A (ko) | 사람 파필로마바이러스(hpv) 16 단백질의 혈청반응성 에피토프 | |
DE69833106D1 (de) | Antigene fusionsproteine, die gal-alpha-1,3-gal-epitope enthalten. | |
CY1111831T1 (el) | Παραγωγα ογκο-συναφους αντιγονου απο την οικογενεια mage και αλληλουχιες νουκλεϊνικου οξεος που κωδικοποιουν αυτα, που χρησιμοποιουνται για την παρασκευη πρωτεϊνων συντηξης και συνθεσεων για εμβολιασμο | |
KR950702635A (ko) | 감쇠 박테리아에서 재조합 융합 단백질의 발현(Expression of recombinant fusion proteins in attenuated bacteria) | |
EP2311952A3 (en) | Antibodies to MRT-1 protein or fragments thereof | |
NZ507378A (en) | Fusion proteins of mycobacterium tuberculosis antigens and their uses | |
DK0523395T3 (da) | Seroreaktive områder på proteinerne E1 og E2 i HPV 16 | |
ATE298798T1 (de) | Fusionsproteine zwischen antigene aminosäuresequenzen und beta - 2- mikroglobulin | |
WO1999003987A3 (fr) | Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie | |
WO1996021734A3 (en) | P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods | |
Yoshimura et al. | Purification and properties of a 75-kilodalton major protein, an immunodominant surface antigen, from the oral anaerobe Bacteroides gingivalis | |
NZ296564A (en) | Method of improving antigenicity of antigens or haptens, fusion with rsv peptides; vaccines, vectors, nucleotides | |
KR910019641A (ko) | 사람 유두종 바이러스(hpv) 18의 단백질상의 혈청 반응성 에피토프 | |
FR2669338B1 (ko) | ||
ATE189961T1 (de) | Impfstoff gegen mycobakterielle infektionen | |
Watts et al. | Mapping of the antigenic determinants of Pseudomonas aeruginosa PAK polar pili | |
KR930012827A (ko) | 항 사람 IgE 모노클로날 항체 | |
MX9801089A (es) | Proteina hibrida que comprende epitopes estimulantes de celula auxiliar t y epitopes de celula b de la proteina de membrana externa mayor chlamydia trachomatis y su uso como vacuna. | |
DE68923006D1 (de) | Fusionsproteine der untereinheit b von choleratoxin und eines heterologen antigens und dafür kodierende rekombinante nukleinsäure. | |
KR900004935A (ko) | 슈도 모나즈 아에루기노사의 지질단백질 i(ompi) | |
RU2206610C2 (ru) | Выделенная и очищенная молекула нуклеиновой кислоты (варианты), плазмидный вектор, выделенный и очищенный высокомолекулярный белок (hmw) нетипичных haemophilus, конъюгат, синтетический пептид | |
AU3379693A (en) | Vaccines and diagnostic assays for haemophilus influenzae | |
ATE248188T1 (de) | Monoklonale antikörper gegen das epitop ypydvpdya,verfahren zu deren herstellung und ihre verwendung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
N231 | Notification of change of applicant | ||
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |